Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma

APMIS

Volumn 112, Issue 2, 2004, Pages 123-132

  Turunen, Nina ^a   Karihtala, Peeter ^a   Mäntyniemi, Anne ^a   Sormunen, Raija ^b   Holmgren, Arne ^c   Kinnula, Vuokko L ^d   Soini, Ylermi ^a,b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breast cancer; Immunohistochemistry; Oxidative stress; p53; Thioredoxin; Thioredoxin reductase

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CARCINOMA IN SITU; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH); TUMOR SUPPRESSOR PROTEIN P53;

EID: 1642523633     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm1120207.x     Document Type: Article

References (58)

1. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991;91:14S-22S.
2. Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Rad Biol Med 2001;31:1287-312.
3. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 1993;69:261-74.
4. Fridovich I, Freeman B. Antioxidant defenses in the lung. Annu Rev Physiol 1986;48:693-702.
5. Crapo JD, Oury T, Rabouille C, Slot JW, Chang LY. Copper-zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci USA 1992;89:10405-9.
6. Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest 1984;74:1398-403.
7. Kinnula VL, Crapo JD, Raivio KO. Biology of disease: generation and disposal of reactive oxygen metabolites in the lung. Lab Invest 1995;73:3-19.
8. Butterfield LH, Meriono A, Golub SH, Shau H. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antiox Redox Signal 1999;1:385-402.
9. Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995;252:199-208.
10. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active site sulfhydryls to a disulfide. Structure 1995;3:239-43.
11. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001;30:421-55.
12. Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000;267:6102-9.
13. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989;264:13963-6.
14. Higashikubo A, Tanaka N, Noda N, Maeda I, Yagi K, Mizoguchi T, et al. Increase in thioredoxin activity of intestinal epithelial cells mediated by oxidative stress. Biol Pharm Bull 1999;22:900-3.
15. Kumar S, Holmgren A. Induction of thioredoxin, thioredoxin reductase and glutaredoxin activity in mouse skin by TPA, a calcium ionophore and other tumor promoters. Carcinogenesis 1999;9:1761-7.
16. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum. Free Radic Biol Med 1999;27:504-14.
17. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999;274:35809-15.
18. Cromlish JA, Roeder RG. Human transcription factor IIIC (TFRIC). Purification, polypeptide structure and the involvement of thiol groups in specific DNA binding. J Biol Chem 1989;264:18100-9.
19. Bannister AJ, Cook A, Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZFL1 but not C/EBP is affected by redox changes. Oncogene 1991;6:1243-50.
20. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res 1992;20:3821-30.
21. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001;159:387-97.
22. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappa B and p53. Mol Cell Biol 1999;19:3485-95.
23. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El Deiry WS, et al. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 1998;58:4531-6.
24. Miyamoto S, Verma IM. Rel/NF-κB/IκB story. Adv Cancer Res 1995;66:255-92.
25. Gerondakis S, Grumont R, Rourke I, Grossman M. The regulation and roles of NF-κB transcription factors during lymphocyte activation. Curr Opin Immunol 1998;10:353-9.
26. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996;274:782-4.
27. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-91.
28. Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 1998;111-112:23-4.
29. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Rad Biol Med 2000;29:312-22.
30. Zhong L, Arnér ES, Ljung J, Åslund F, Holmgren, A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem 1998;273:8581-91.
31. Zhong L, Arnér ES, Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci USA 2000;97:5854-9.
32. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000;24:53-60.
33. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, et al. Expression and growth-promoting effect of adult T-cell leukaemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992;69:2091-7.
34. Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, et al. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 2001;95:198-204.
35. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
36. Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, et al. Coexpression of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 1991;68:1583-91.
37. Ueno M, Matsutani Y, Nakamura H, Masutani H, Yagi M, Yamashiro H, et al. Possible association of thioredoxin and p53 in breast cancer. Immunol Lett 2000;75:15-20.
38. Matsutani Y, Yamamuchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K, et al. Inverse correlation of thioredoxin expression with estrogen receptor-and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001;7:3430-6.
39. Elston CW, Ellis IO. Classification of Malignant Breast Disease. In: Elston CW, Ellis IO. The Breast. Systemic Pathology, Volume 13. Edinburgh: Churchill Livingstone, 1998;239-47.
40. Holland R, Hendricks JHCL, Verbeck ALM, Mravunac M, Schuurmans-Stekhoven JH. Extent, distribution and mammographic/histological correlations of breast ductal carcinomas in situ. Lancet 1990;335:519-22.
41. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 1982;21:6628-33.
42. Rozell B, Hansson HA, Luthman M, Holmgren A. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rat. Eur J Cell Biol 1985;38:79-86.
43. Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, et al. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 1996;56:5765-70.
44. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, et al. Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 2000;267:6110-7.
45. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.
46. Maruyama T, Sachi Y, Furuke K, Kitaoka Y, Kanzaki H, Yoshimura Y, et al. Induction of thioredoxin, a redox-active protein, by ovarian steroid hormones during growth and differentiation of endometrial stromal cells in vitro. Endocrinology 1999;140:365-72.
47. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappa. J Biol Chem 1999;274:27891-7.
48. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996;56:5330-3.
49. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, et al. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 1999;274:3182-8.
50. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997;94:3633-8.
51. Ueda S, Nakamura H, Masutani H, Sasada T, Yonehara S, Takabayashi A, et al. Redox regulation of caspase-3-like protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol 1998;161:6689-95.
52. Sun QA, Wu Y, Zappacosta F, Jeang KT, Lee BJ, Hatfield DL, et al. Redox regulation of cell signalling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem 1999;273:8581-91.
53. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001;7:1750-7.
54. Rubartelli A, Bonifaci N, Sitia R. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res 1995;55:675-80.
55. Freemerman AJ, Gallegos A, Powis G. Nuclear factor KB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res 1999;59:4090-4.
56. Merrill GF, Dowell P, Pearson GD. The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase. Cancer Res 1999;59:3175-9.
57. Pearson GD, Merrill GF. Deletion of Saccharomyces cerevisae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem 1998;273:5431-4.
58. Tamir S, Izrael S, Vaya J. The effect of oxidative stress on ERalpha and ERbeta expression. J Steroid Biochem Mol Biol 2002;81:327-32.